PMID- 37358825
OWN - NLM
STAT- MEDLINE
DCOM- 20230908
LR  - 20230911
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Print)
IS  - 0586-7614 (Linking)
VI  - 49
IP  - 5
DP  - 2023 Sep 7
TI  - Social Psychopharmacology: Novel Approaches to Treat Deficits in Social 
      Motivation in Schizophrenia.
PG  - 1161-1173
LID - 10.1093/schbul/sbad094 [doi]
AB  - BACKGROUND AND HYPOTHESIS: Diminished social motivation is a negative symptom of 
      schizophrenia and leads to severe functional consequences for many patients 
      suffering from the illness. However, there are no effective medications available 
      to treat this symptom. Despite the lack of approved treatments for patients, 
      there is a growing body of literature on the effects of several classes of drugs 
      on social motivation in healthy volunteers that may be relevant to patients. The 
      aim of this review is to synthesize these results in an effort to identify novel 
      directions for the development of medications to treat reduced social motivation 
      in schizophrenia. STUDY DESIGN: In this article, we review pharmacologic 
      challenge studies addressing the acute effects of psychoactive drugs on social 
      motivation in healthy volunteers and consider how these findings may be applied 
      to deficits in social motivation in schizophrenia. We include studies testing 
      amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, 
      serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides. 
      STUDY RESULTS: We report that amphetamines, MDMA, and some opioid medications 
      enhance social motivation in healthy adults and may represent promising avenues 
      of investigation in schizophrenia. CONCLUSIONS: Given the acute effects of these 
      drugs on behavioral and performance-based measures of social motivation in 
      healthy volunteers, they may be particularly beneficial as an adjunct to 
      psychosocial training programs in patient populations. It remains to be 
      determined how these medications affect patients with deficits in social 
      motivation, and in which contexts they may be most effectively administered.
CI  - Published by Oxford University Press on behalf of the Maryland Psychiatric 
      Research Center 2023.
FAU - Bershad, Anya K
AU  - Bershad AK
AUID- ORCID: 0000-0002-3011-3730
AD  - Department of Psychiatry and Biobehavioral Sciences, University of California, 
      Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles, 
      CAUSA.
FAU - de Wit, Harriet
AU  - de Wit H
AUID- ORCID: 0000-0002-7211-8994
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 
      Chicago, ILUSA.
LA  - eng
GR  - R01 DA002812/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Schizophrenia
MH  - Motivation
MH  - *Psychopharmacology
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use
MH  - *Apathy
PMC - PMC10483474
OTO - NOTNLM
OT  - Amotivation
OT  - approach and avoidance
OT  - human behavioral pharmacology
COIS- HdW is on the Board of Directors of PharmAla Biotech and consultant to Awakn Life 
      Sciences and Gilgamesh Pharmaceuticals. These are unrelated to this manuscript.
EDAT- 2023/06/26 13:07
MHDA- 2023/09/08 06:43
PMCR- 2024/06/26
CRDT- 2023/06/26 11:22
PHST- 2024/06/26 00:00 [pmc-release]
PHST- 2023/09/08 06:43 [medline]
PHST- 2023/06/26 13:07 [pubmed]
PHST- 2023/06/26 11:22 [entrez]
AID - 7207745 [pii]
AID - sbad094 [pii]
AID - 10.1093/schbul/sbad094 [doi]
PST - ppublish
SO  - Schizophr Bull. 2023 Sep 7;49(5):1161-1173. doi: 10.1093/schbul/sbad094.